טוען...
Alzheimer's disease drug development pipeline: 2019
INTRODUCTION: Alzheimer's disease (AD) has few available treatments, and there is a high rate of failure in AD drug development programs. Study of the AD drug development pipeline can provide insight into the evolution of drug development and how best to optimize development practices. METHODS:...
שמור ב:
| הוצא לאור ב: | Alzheimers Dement (N Y) |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6617248/ https://ncbi.nlm.nih.gov/pubmed/31334330 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2019.05.008 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|